Quidel Corporation (QDEL): Price and Financial Metrics


Quidel Corporation (QDEL)

Today's Latest Price: $227.72 USD

3.51 (1.57%)

Updated Jan 28 10:39am

Add QDEL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

QDEL Stock Summary

  • Price to trailing twelve month operating cash flow for QDEL is currently 39.57, higher than 88.08% of US stocks with positive operating cash flow.
  • Over the past twelve months, QDEL has reported earnings growth of 454.14%, putting it ahead of 96.75% of US stocks in our set.
  • Revenue growth over the past 12 months for Quidel Corp comes in at 94.96%, a number that bests 94.49% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to QDEL, based on their financial statements, market capitalization, and price volatility, are IRBT, NATI, FLIR, MKSI, and ATHM.
  • QDEL's SEC filings can be seen here. And to visit Quidel Corp's official web site, go to www.quidel.com.

QDEL Stock Price Chart Interactive Chart >

Price chart for QDEL

QDEL Price/Volume Stats

Current price $227.72 52-week high $306.72
Prev. close $224.21 52-week low $72.99
Day low $221.71 Volume 92,832
Day high $229.99 Avg. volume 1,056,543
50-day MA $198.48 Dividend yield N/A
200-day MA $206.47 Market Cap 9.58B

Quidel Corporation (QDEL) Company Bio


Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.

QDEL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$227.72$148.04 -34%

Below please find a table outlining a discounted cash flow forecast for QDEL, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quidel Corp ranked in the 41th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Quidel Corp, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 44.05; that's higher than 91.42% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 7.15% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 51.49% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-35%
1%-35%
2%-34%
3%-33%
4%-33%
5%-32%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as QDEL, try STE, MEDP, AMGN, INBP, and NVS.


QDEL Latest News Stream


Event/Time News Detail
Loading, please wait...

QDEL Latest Social Stream


Loading social stream, please wait...

View Full QDEL Social Stream

Latest QDEL News From Around the Web

Below are the latest news stories about Quidel Corp that investors may wish to consider to help them evaluate QDEL as an investment opportunity.

Is Quidel Corporation's (NASDAQ:QDEL) Latest Stock Performance A Reflection Of Its Financial Health?

Quidel's (NASDAQ:QDEL) stock is up by a considerable 21% over the past month. Given that the market rewards strong...

Yahoo | January 26, 2021

Top Ranked Growth Stocks to Buy for January 25th

Top Ranked Growth Stocks to Buy for January 25th

Yahoo | January 25, 2021

Boston Scientific (BSX) Enhances Core Business With Buyout

Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.

Yahoo | January 22, 2021

Global Urinalysis Market 2021:Opportunities, Challenges with Top Trending Key Players -Beckman Coulter Inc, Trinity Biotech, Sysmex Corporation, Quidel Corporation, Bio-Rad Laboratories, Inc

Global urinalysis market is expected to reach USD 8,767.60 million by 2027 from USD 4,994.50 million in 2019 growing with the substantial CAGR of 7.3% in the forecast period of 2020 to 2027. The Urinalysis market report will help all the

OpenPR | January 20, 2021

Quidel Flashes Improved Relative Price Strength

Quidel had its Relative Strength (RS) Rating upgraded from 67 to 75 Tuesday — a welcome improvement for the producer of rapid diagnostic tests, but still short of the 80 or better score you look for. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary RS Rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.

Yahoo | January 19, 2021

Read More 'QDEL' Stories Here

QDEL Price Returns

1-mo 25.69%
3-mo -15.12%
6-mo -19.38%
1-year 184.26%
3-year 375.90%
5-year 1,236.38%
YTD 26.76%
2020 139.44%
2019 53.69%
2018 12.62%
2017 102.38%
2016 1.04%

Continue Researching QDEL

Here are a few links from around the web to help you further your research on Quidel Corp's stock as an investment opportunity:

Quidel Corp (QDEL) Stock Price | Nasdaq
Quidel Corp (QDEL) Stock Quote, History and News - Yahoo Finance
Quidel Corp (QDEL) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9072 seconds.